checkAd

Promising Developments in Breast Cancer Treatments Ahead in 2022

VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ -- USA News Group  -  So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis. In just the first half of January, the market witnessed the identification of MAPK4 as a potential target for triple-negative breast cancer (TNBC), and a lasting survival benefit in HER2+ metastatic breast cancer from adding tucatninib to treatment with trastuzumab and capecitabine. There are plenty more developments to come from biotech companies working into 2022 on new treatments for breast cancer including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Illumina, Inc. (NASDAQ:ILMN), Zai Lab Limited (NASDAQ:ZLAB), Merus N.V. (NASDAQ:MRUS), and Veru Inc.(NASDAQ:VERU).

Updating the market on its flagship immunotherapeutic agent pelareorep, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) laid out its primary breast cancer achievements in 2021, as well as its 2022 program to come in its latest letter to shareholders.

For breast cancer patients treated with pelareorep Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- in IND-213—as seen from study results delivered in 2017.

Through a series of data analysis, Oncolytics chose to focus on the three achievable objectives put in place by regulators and the company's pharma partners, representing important steps towards a registrational study. This included: 1. Confirming that pelareorep works through an immunotherapeutic mechanism of action; 2. Determining whether pelareorep synergizes with immune checkpoint inhibitors; and 3. Identifying a biomarker to select patients who are likely to have better clinical outcomes.

In the shareholders letter, Dr. Matt Coffey, President & CEO of Oncolytics Biotech, wrote: "I am pleased to report that we are well on our way to achieving these three objectives."

Back in April 2021, Oncolytics presented cohort data from its AWARE-1 study, being conducted with Roche, showing that the first two objectives referenced above had been achieved.

By December at the 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics presented a positive safety update from its IRENE Phase 2 Triple-Negative Breast Cancer Trial evaluating the safety and efficacy of pelareorep in combination with the anti-PD-1 checkpoint inhibitor retifanlimab from Incyte for second- or third-line treatment of patients with metastatic triple-negative breast cancer (TNBC).

Seite 1 von 4


Diskussion: Illumina


0 Kommentare
Nachrichtenquelle: PR Newswire (engl.)
12.01.2022, 16:58  |  139   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Promising Developments in Breast Cancer Treatments Ahead in 2022 VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - USA News Group  -  So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer …

Nachrichten des Autors

Titel
Titel
Titel
Titel